A7089458
Arformoteroltartrate , 10mMinDMSO , 200815-49-2
CAS NO.:200815-49-2
Empirical Formula: C19H24N2O4.C4H6O6
Molecular Weight: 494.494
MDL number: MFCD07785830
EINECS: 200-589-5
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB280.00 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 184° |
| storage temp. | Refrigerator, Under Inert Atmosphere |
| solubility | DMSO (Slightly, Sonicated), Methanol (Slightly, Heated, Sonicated) |
| form | Solid |
| color | White to Pale Brown |
| InChIKey | FCSXYHUNDAXDRH-LFJODZMVNA-N |
| SMILES | C1(NC=O)=C(C=CC([C@@H](O)CN[C@H](C)CC2C=CC(=CC=2)OC)=C1)O.[C@@H]([C@H](C(O)=O)O)(C(O)=O)O |&1:8,12,25,26,r| |
Description and Uses
Sepracor’s Brovana®, a nebulized long acting bronchodilator, was launched in the U.S. in April 2007. The β2- adrenoceptor agonist is indicated for the twice-daily, longtermmaintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. It is the first long-acting nebulized bronchodilator approved by the FDA for this indication.
Anti-asthmatic and bronchodilator.
Safety
| Symbol(GHS) | ![]() ![]() GHS08,GHS06 |
| Signal word | Danger |
| Hazard statements | H302-H361-H334-H331-H351-H372 |
| Precautionary statements | P264-P270-P301+P312-P330-P501-P201-P202-P281-P308+P313-P405-P501-P260-P264-P270-P314-P501-P201-P202-P281-P308+P313-P405-P501-P261-P285-P304+P341-P342+P311-P501-P261-P271-P304+P340-P311-P321-P403+P233-P405-P501 |





![Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, [S-(R*,S*)]-](https://img.chemicalbook.com/CAS/GIF/67346-50-3.gif)
![(αR)-3-Amino-4-hydroxy-α-[[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]methyl]benzenemethanol](https://img.chemicalbook.com/CAS/20210111/GIF/245759-62-0.gif)

![Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, [R-(R*,S*)]-](https://img.chemicalbook.com/CAS/GIF/67346-51-4.gif)